Search all trials

Find therapies in clinical trials near you – page 37

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Transitional cell cancer of the renal pelvis and ureter+1

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Padeliporfin

Contact Research Centre

Lupus nephritis+1

Not recruiting

Investigational

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Vemircopan

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Registered drugNo placebo

Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab

Contact Research Centre

Bacterial infection

Not recruiting

Registered drugNo placebo

Study of Temocillin and Meropenem for Patients with Infections Caused by Resistant Enterobacteriaceae

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ertapenem Sodium

Contact Research Centre

Metastases to central nervous system+1

Not recruiting

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Selpercatinib

Contact Research Centre

Ovarian cancer

Not recruiting

Registered drugNo placebo

Study of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Corneal dystrophy

Not recruiting

Investigational

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Ripasudil

Contact Research Centre

Heart failure with preserved ejection fraction

Not recruiting

Investigational

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Tovinontrine

Contact Research Centre

Dry age-related macular degeneration

Not recruiting

Investigational

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Danicopan

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Registered drug

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Tildrakizumab

Contact Research Centre

Hidradenitis

Not recruiting

Investigational

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Spesolimab

Contact Research Centre

Find therapies in clinical trials near you – page 37

564 trials match your criteria

Transitional cell cancer of the renal pelvis and ureter+1

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Lupus nephritis+1

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

HER2 positive breast cancer

Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

Bacterial infection

Study of Temocillin and Meropenem for Patients with Infections Caused by Resistant Enterobacteriaceae

Metastases to central nervous system+1

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

Non-small cell lung cancer

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Ovarian cancer

Study of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation

Corneal dystrophy

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

Heart failure with preserved ejection fraction

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Dry age-related macular degeneration

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Psoriatic arthropathy

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Hidradenitis

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.